Logo Prima Biomed


Welcome to the Newsroom

01 March 2017

USA Patent Grants for IMP321 in Cancer


ENGLISH

 

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, the “Company”) announces the granting of patent number 9,579,382 entitled “Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response” by the United States Patent Office.

 

(...)